TRUDI: TDXD+Durva in HER2+/Low IBC

NCT05795101 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

63

Enrollment

OTHER

Sponsor class

Conditions

Invasive Breast Cancer
Inflammatory Breast Cancer Stage III
HER2-positive Breast Cancer
HER2 Low Breast Adenocarcinoma
Breast Cancer

Interventions

DRUG: Trastuzumab deruxtecan
DRUG: Durvalumab

Sponsor

Filipa Lynce, MD

Collaborators

[object Object]
[object Object]